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1. INTRODUCTION 
 With many drugs, the basic goal of therapy is to achieve a steady-state blood or tissue 
level that is therapeutically effective and non-toxic for an extended period of time.  The design of 
proper dosage regimens is an important element in accomplishing this goal1. 
 The idealized objective points to the two aspects most important to drug delivery, 
namely, spatial placement and temporal delivery of a drug.  Spatial placement relates to targeting 
a drug to a specific organ of tissue, while temporal delivery refers to controlling the rate of drug 
delivery to the target tissue.   
            An appropriately designed sustained release drug delivery system can be a major advance 
toward solving these two problems.  The bulk of research has been directed at oral dosage forms 
that satisfy the temporal aspect of drug delivery, but many of the newer approaches under 
investigation may allow for spatial placement as well. 
1.1 Conventional drug therapy 
There are several potential problems inherent in multiple dosage therapy: 
 If the dosing is not appropriate for the biological half-life of the drug, large “Peaks” and 
“Valleys” in the drug blood level may result. For example, drugs with short half-lives require 
frequent dosing to maintain constant therapeutic levels. 
 The drug blood level may not be within the therapeutic range at sufficiently early times, an 
important consideration for certain disease states. 
                                    2 
 Patient noncompliance with the multiple-dosing regimen can result in failure of this 
approach. 
 Frequently these problems are significant enough to make drug therapy with conventional 
dosage forms less desirable than sustained release drug therapy.  This fact, coupled with the 
intrinsic inability of conventional dosage forms to achieve spatial placement, is a compelling 
motive for investigation of sustained-release drug delivery systems. 
1.2. Sustained Release Drug Therapy 
 Conventional dosage forms include solutions, suspensions, capsules, tablets, emulsions, 
aerosols, foams, ointments and suppositories. For this discuss, these dosage forms can be 
considered to release their active ingredients into an absorption pool immediately.  This is 
illustrated in the following simple kinetic scheme2: 
 
 Dosage           Kr  Absorption        Ka                   Target            Ke 
  Form       drug release    Pool            drug release    Area        Elimination 
    
 The absorption pool represents a solution of the drug at the site of absorption, and the 
terms Kr, Ka and Ke are first – order rate constants for drug release, absorption and overall 
elimination, respectively.  Immediate release from a conventional dosage form implies that 
Kr>>>Ka or that observation of drug across a biological membrane, such as the intestinal 
epithelium, is the rate-limiting step in delivery of the drug to its target area. 
For non immediate – release dosage forms, Kr<<<Ka, that is, release of drug from the 
dosage form the rate-limiting step.   This causes the above kinetic to reduce to the following: 
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 Dosage          Kr          Target            Ke 
  Form       drug release        Area                 Elimination 
    
Non-immediate-release delivery systems may be divided conveniently into four categories3:  
                            
                                            1. Delayed release 
                                            2. Sustained release 
                                       a. Controlled release 
                                                             b. Prolonged release 
                                              3. Site-specific release 
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                                        4. Receptor release 
                                                   A-Control Release Formulation 
                                                   B-Sustain Release Formulation 
 C-Conventional Release formulation 
Figure: 1.1 A Hypothetical plasma concentration-time profile from conventional Sustained 
and control delivery formulations 
In the case of new drug delivery systems, which are based on controlled of programmed drug 
delivery methods in the vicinity of target tissue, this undeniable fluctuation of drug  levels 
(concentration) between toxic level and sub-therapeutic level can be greatly reduced.  This 
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controlled drug-therapy offers a method for which therapeutic action is enhanced and the 
dangerous toxic level eliminated. 
Digital computers have become integral components of modem methods of analysis.  
Applications of these devices to analytical instrumentation have increase with advances in 
computer technology.  Initially computers were used to automate conventional calculations and 
existing instruments.  Later new measurement methods were developed which were possible 
only through the use of computerized instruments and high-speed data processing techniques. 
 In many cases, identification can be made on a fraction of a milligram, or even on several 
micrograms, of sample.  Identification on the milligram scale is routine, of course, not all 
molecules yield so easily.   
             Chemical manipulations may be necessary information obtained from the spectra will 
permit intelligent selection of chemical treatment, and energy probe methodology can be applied 
to the resulting products. 
 
1.2.1 Potential Advantages of Sustained Drug Therapy 
 Avoid patient compliance problems. 4 
  Employ less total drug. 
 Minimize or eliminate local side effects. 
 Minimize or eliminate systemic side effects. 
 Obtain less potentiating or reduction in drug activity with chronic use. 
 Minimize drug accumulation with chronic dosing. 
 .Improve efficiency in treatment 
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 Cure of control condition more promptly 
 Improve control of condition, i.e. reduce fluctuation in drug level 
 Improve bioavailability of some drugs 
 Make use of special effects, e.g. sustained-release aspirin for                                                                        
relief of arthritis by dosing before bedtime. 
 
1.3. Drug Properties Relevant to Sustained – release Formulation 
 Discovery, testing and marketing of new chemical entities, the so – called medicinal 
agents, is what differentiates the pharmaceutical industry from many other enterprises. 
 The primary objective is to determine the impact of various factors that have forced the 
drug industry to direct efforts towards development of modified – release or so – called 
specialized drug delivery systems. 
 In developing a formulation, product of process, pharmaceutical of otherwise, is rarely 
known right from the start.  Out own past experience, scientific theory, and the contents of the 
scientific and technical literature may all be of help, but we will still need to do experiments, 
whether to answer our questions or to conform what we already believe to be the case.  And 
before starting the experimentation, we will need to decide what the experiment is actually going 
to be.  We require an experimental strategy. 
 The sustained-release products are often designed with an initial dose intended to 
establish rapidly therapeutic drug blood levels and additional drug intended to maintain those 
levels for prolonged periods.  Those products providing only the slow-release Component and 
lacking the immediate-release component have sometimes been termed prolonged release. 
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 Product formulation if often considered an art, the formulator‟s experience and creativity 
providing the “raw material” for the creation of a new product.  Given the same active ingredient 
and a description of the final marketed producer, two different scientists will very likely concoct 
different formulations.  Certainly, human input is an essential ingredient of the creative process.  
            The term “sustained release” is known to have existed in the medical and pharmaceutical 
literature for many decades.  It has been constantly used to describe a pharmaceutical dosage 
form formulated to retard the release of a therapeutic agent such that its appearance in the 
systemic circulation is delayed and/or prolonged and its plasma profile is sustained in duration. 
             Initial progress in product development rests heavily on a thorough understanding of the 
absorption distribution and elimination characteristics of a drug.  Absorption, distribution and 
elimination processes begin when a dose is administered, and may govern the appearance of any 
therapeutic effect.  Pharmacokinetics is used to quantitate these processes. 
 
1.3.1 Physicochemical Properties 
 A more is an important tool in the development5 of the “best” formulation, in the 
understanding of the drug‟s biopharmaceutical characteristics, and in interpretation of possible 
risks, such as potential food effect on bioavailability or interaction with other drugs.  
 Methods for the determination of solubility have been thoroughly reviewed.  Solubility is 
normally highly dependent on temperature, and so the temperature must be recorded for each 
solubility measurement.  Plots of solubility against temperature are commonly used for 
characterizing pharmaceutical solids. 
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 The historical evolution of this approach to predicting solubility and to predicting the 
deviations from ideal solubility based on theoretical considerations of the interaction between 
solute and solvent has been reviewed.  
1.3.1.1 Aqueous solubility and pKa 
 The aqueous solubility of a drug influences its dissolution rate, which in turn establishes 
its concentration in solution and hence the driving force for diffusion across membranes.  
Dissolution rate is related to aqueous solubility as shown by the Noyes – Whitney equation 
which, under sink condition, is  
dc /dt = KDACs 
  dc/dt= dissolution rate 
   KD = dissolution rate constant 
     A = total surface area of the drug particles and 
    Cs = aqueous saturation solubility of the drug 
 The dissolution rate is constant only if surface area, A, remains constant, but the 
important point to note is that initial rate is proportional directly to aqueous solubility Cs.  
Therefore, the aqueous solubility of a drug can be used as a first approximation of its Dissolution 
rate.  Low solubility limits the dissolution rate and hence the absorption of many drugs. 
 In general, extreme in the aqueous solubility of a drug are undesirable for formulation 
into a sustained release product.  A drug with very low solubility and a slow dissolution rate will 
exhibit dissolution-limited absorption and yield an inherently sustained blood level.  In most 
instances, formulation of such a drug into a sustained released system is redundant. 
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1.3.1.2 Partition coefficient 
 Between the time that a drug is administered and the time it is eliminated from the body, 
it must diffuse through a variety of biological membranes which act primarily as Lipid-like 
barriers.  
 A major criterion in evaluation of the ability of a drug to penetrate these lipid 
membranes is its apparent oil/water partition coefficient, defined as  
    K = Co/Cw 
 Co  = total concentration of all forms of the drug. E.g. ionized and unionized, in some 
organic phased at equilibrium, and  Cw  = total concentration of all forms in an aqueous phase at 
equilibrium 
 
Figure: 1.2 Typical relationship between drug activity and partition coefficient, K, 
Generally known as the Hansch correlation 
              Drugs with a partition coefficient that either is extremely higher of lower that the 
optimum are, in general, poorer candidates for formulation into sustained release dosage forms. 
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1.3.1.3 Drug Stability 
 Of importance for oral dosage forms is the loss of drug through acid hydrolysis and/or 
metabolism in the GI tract.  Since a drug in the solid state undergoes degradation at a much 
slower rate than a drug in suspension or solution, it would be seen possible to improve 
significantly the bioavailability of a drug, which is unstable in the GI tract by placing it in a 
slowly available sustained release form.  For those drugs that are unstable in the stomach, the 
appropriate sustaining unit would be one that releases its contents only in the intestine. 
 However, most sustained-release systems currently in use release their contents over the 
entire length of the GI tract.  Delivery systems that remains localized in a certain area of the GI 
tract and a act as reservoir for drug release are much advantageous for drug that not suffer from 
stability problems but have other bioavailability problems as well.  
1.3.1.4 Protein Binding 
 Distribution of the drug into the extra vascular space is governed by the equilibrium 
process of dissociation of the drug from the protein.  The drug-protein complex can serve 
therefore as a reservoir in the vascular space for sustained drug release to extra vascular tissues, 
but only for those drugs that exhibit a high degree of binding. 
          Extensive binding to plasma proteins will be evidenced by a long half-life of elimination 
for the drug, and such drugs generally do not require a sustained-release dosage form.  However, 
drugs that exhibit a high degree of binding to plasmas proteins also might bind to biopolymer in 
the GI tract, which could have an influence on sustained drug delivery. 
           The main forces of attraction responsible for bindings are Vanderwaals forces, hydrogen 
bonding and electrostatic forces.  In general, charged compounds have a greater tendency to bind 
a protein than uncharged compounds, due to electrostatic effects.  The presence of a hydrophobic 
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moiety of the drug molecule also increases its binding potential.  Some drugs that exhibit greater 
than 95% binding at therapeutic levels are Amitriptyline, Bischydroxycoumarin, Diazepam, 
Diazoxide, Dicumarol, and Novobioocin.  
1.3.1.5 Molecular Size and Diffusivity 
 In addition to diffusion through these biological membranes, drugs in many sustained-
release systems must diffuse through a polymeric membrane or matrix that is used to control 
their release kinetics.  The ability of a drug to diffuse through polymeric membrane or matrix 
that is used to control their release kinetics membranes is a function of its diffusivity (diffusion 
coefficient). 
 An important influence upon the value of the diffusivity, D, in polymers is the molecular 
size (or molecular weight) of the diffusing species.  In most polymers, it is possible to relate log 
D empirically to some function of molecular size.  The value of D thus is related to the size and 
shape of the cavities as well as size and shape of drugs. 
 1.3.2 Biological Properties 
1.3.2.1 Absorption 
 The rate, extent and uniformity of absorption of a drug are important factors when 
considering its formulation into a sustained-release system; since the rate limiting step in drug 
delivery from a sustained-release system is its release from the dosage form, rather than 
absorption, a rapid rate of absorption of the drug relative to its release is essential if the system is 
to be successful.  The extent and uniformity of the absorption of a drug, as reflected by its 
bioavailability and the fraction of the total dose absorbed, may be quite low for a variety of 
reasons.  This usually is not a prohibitive factor in its formulation into a sustained-release 
system. 
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 Some possible reasons for a low extent of absorption are poor water solubility, small 
coefficient, acid hydrolysis and metabolism, or site-specific absorption. The latter reason also is 
responsible for non-uniformity of absorption. Many of these problems can be overcome by an 
appropriately designed sustained-release system, as exemplified by the discussion under the 
potential advantages of sustained drug therapy5. 
1.3.2.2 Distribution 
 The distribution of a drug into vascular and extravascular spaces in the body is an 
important factor in its overall elimination kinetics.  This, in turn, influences the formulation of 
that drug into a sustained-release system, primarily by restricting the magnitude of the release 
rate and the dose size which can be employed.  The apparent volume of distribution is merely 
proportionality constant which relates drug concentration in the blood or plasma to the total 
amount of drug in the body. 
 The magnitude of the apparent volume of distribution can be used as a guide for 
additional studies and as a predictor for drug dosing regimen and hence the need to employ 
sustained-release system. 
1.3.2.3 Metabolism 
 The metabolic conversion of a drug to another chemical form usually can be considered 
in the design of a sustained-release system for that drug.  As long as the location, rate and extent 
of metabolism are known and the rate constant(s) for the process (es) are not too large, 
successful sustained-release products can be developed.  
 There are two factors associated with the metabolism of some drugs; however that 
present problems of their use in sustained-release systems. One is the ability of the drug to 
induce or inhibit enzyme synthesis; this may result in a fluctuating drug blood level with chronic 
                                    13 
dosing.  The other is a fluctuating drug blood level due to intestinal (or other tissue) metabolism 
or through a hepatic first-pass effect.  Examples of drugs that are subject to intestinal metabolism 
upon oral dosing are Hydralazine, Salicylamide, Nitroglycerine, Isoproterenol, Chlorpromazine 
and Levodopa. Examples of drugs that undergo extensive first-pass hepatic metabolism are 
Propoxyphene, Nortriptyline, Phenacetine, Propranolol and Lidocaine.  
`1.3.2.4 Elimination and Biological Half-life 
 The rate of elimination of a drug is quantitatively described by its biological half-life, 
t1/2- The half-life of a drug is related to large release rates and large doses. At the other extreme, 
a drug with a half-life of greater than 8 hours also probably should not be used; in most 
instances, formulation of such a drug into a sustained-release system its apparent volume of 
distribution Vd and its systemic clearance may affected. A drug with a short half-life requires 
frequent dosing and this makes it a desirable candidate for a sustained-release formulation. 
In general, however, a drug with a half-life, if less than 2 hours probably should not be 
used since such systems will require unacceptably large release rates and large doses.  At the 
other extreme, a drug with a half-life of greater than 8 hours also probably should not be used; in 
most instances, formulation of such a drug into a sustained-release system is unnecessary. 
Some examples of drug with half-lives of less than 2 hours are Ampicillin, Cephalexin, 
Cloxacillin, Furosemide, Levodopa, Penicillin G and Propylthiouracil. Examples of those with 
half-lives of greater than 8 hours are Dicumarol, Diazepam, Digitoxin, Digoxin, Guanethidine, 
Phenytoin and Warfarin. 
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1.3.2.5 Side effects and Safety Considerations 
For some drugs, the incidence of side effects, in addition to toxicity, is believed to be 
related to their plasma concentration. As mentioned in the discussion on the potential advantages 
of sustained drug therapy, a sustained-release system can at times, minimize side effects for a 
particular drug by controlling its plasma concentration and using less total drug over the time 
course of therapy. 
            The most widely used measure of the margin of safety of a drug is its therapeutic index, 
TI, defined in the following equation: 
TI = TD50/ED50 
TD50 is the median toxic dose 
ED50 is the median effective dose. 
 The value of TI varies from as little as unity, where the effective dose is also producing toxic 
symptoms, to several thousand. For very "potent" drugs, whose therapeutic concentration range 
is narrow, the value of TI is small. In general, the larger the value of TI, the safer is the drug. 
Drugs with very small values of TI usually are poor candidates for formulation into sustained-
release products primarily due to technological limitations of precise control over release rates. 
Examples of drugs with values of TK10 are Aprobarbital, Digitoxin, Phenobarbital and Digoxin.  
1.3.2.6 Dose Size 
             Since a sustained-release is designed to alleviate repetitive dosing, it naturally will 
contain a greater amount of drug than a corresponding conventional form. The typical 
administered dose of a drug in the conventional dosage form will give some indication ofthe total 
amount needed in the sustained-release preparation. For those drugs requiring-large conventional 
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doses, the volume of the sustained dose may be so large as that to be Impractical or 
unacceptable, depending on the route of administration. The same may be true of drugs, which 
require a large release rate from the sustained-release system, e.g. drugs with short half-lives. 
  Two geometric systems can be considered, in involving unidirectional leaching of 
extraction from a simple planar surface and a second involving three-dimensional leaching of 
extraction from a spherical dosage form, such as a pellet. This corresponds most closely to the 
release process from an insoluble matrix (tablet) or certain sustained or controlled-release pellets. 
The mechanisms of release from these systems can be treated in two ways: (a) Extraction of the 
medicament by a simple diffusion process through enveloping homogeneous matrix, (b) 
Leaching of the medicament by the bathing fluid, which is able to enter the drug-matrix phase 
through pores, cracks and intergranular spaces. 
 
When tablet ingredients are sensitive to moisture and are unable to withstand elevated 
temperature during drying and when the tablet ingredients have sufficient inherent binding or 
cohesive properties, slugging may be used to form granules. This method is known as dry 
granulation of pre-compression method or the double compression method. 
A matrix is a uniform mixture of drug, excipients, and (e.g.) polymer that is 
homogeneously fixed in a solid dosage form.  
1.4. Selection of drug for Sustained-release drug delivery systems 
Judicious choice of the drug substance is the most important decision in the successful 
development of a sustained-release product, 
Several categories of drug have potential for their therapeutics improvement of efficacy 
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via sustained-release oral routes e.g. Anti-anginal, Anti-inflammatory, Antihistaminic, Anti-
gastric resistant agents, Antipsychotic agents and Anti-diabetic drugs of agents. 
The common goal for increased duration is twice a day, or when feasible, once a day. 
Several properties of the drug itself can lead to the achievement of a 12 to 24 hours oral 
prolonged release dosage form. Some of the characteristics mitigating against success are the 
following: 
1.   Very short half-life and/or a relatively large single dose. 
2.   Long half-life.  
3.   Potent drug with a low margin safety. 
4.   Poorly soluble and/or poorly absorbed. 
5.   Biological activity not a function of core in blend. 
6.   Absorption primarily active through a 'window'. 
7.   Large first-pass metabolism. 
     The selection of both the drug and retardant polymers along with the filler excipients 
will impact on the mechanism and rates of drug release from monolithic systems. Cellulose 
derivatives and acrylic resin polymers comprise the group of polymers that are presently 
available as aqueous coatings for pharmaceutical dosage forms. These polymers in the dry state 
have been utilized in matrix type tablet formulations by directly compressing. 
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1.5 Matrix systems 
                  A polymer and active agent have been mixed to form a homogeneous system referred 
to as a matrix system. 7: 
                 To control the release of the drug, which are having different solubility properties 
hydrophobic, and hydrophilic matrices have been used. 
                 For water-soluble drugs, the hydrophobic and hydrophilic polymeric matrices are 
mixed. The following physicochemical properties of the drug are influence the design of oral 
controlled drug matrix systems. 
•    Solubility 
•    Partition coefficient and molecules weight. 
•    Drug stability 
•    Protein binding. 
Release from this matrix system occurs based on successive processes of: 
•     Hydration of the cellulosic polymer. 
•     Gel formation on the polymer's surface. 
•     Tablet erosion, & the subsequent & continuous release of drug. 
     After ingestion, the tablet is wetted by gastric fluid and the polymer begins to hydrate. 
A gel layer forms around surface of the tablet and an initial quantity of drug is exposed and 
released. As water penetrates further into the tablet the thickness of the gel layer is increased and 
soluble drug diffuses through the gel layer. As the outer layer becomes fully hydrated it erodes 
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from the tablet core. 
    If the drug is insoluble, it is released as such with the eroding gel layer. Thus, the rate 
of drug release is controlled by the processes of diffusion and tablet erosion. 
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                                                     2. AIM AND OBJECTIVE 
         The objective of the study is to design and evaluated of Esomeprazole oral 
sustained release tablets using natural polymers. 
                   Esomeprazole is a proton pump inhibitor which reduces acid secretion through 
inhibition of the H+ / K+ ATPase in gastric parietal cells. By inhibiting the functioning of this 
transporter, the drug prevents formation of gastric acid. 
It is used in the treatment of dyspepsia and peptic ulcer disease  
       Since Esomeprazole is a potent drug used in the treatment of Peptic ulcer its dosing 
intervals generally varies based on the intensity of the ulcers. Hence to decrease the number of 
dosing intervals and to sustain the drug Esomeprazole sustain release dosage forms are being 
designed.The main objective of the work is to develop a simple, cost effective oral sustained 
release dosage form of Esomeprazole using natural polymers, which shows good stability and 
sustainability of the drug thus decreasing the number of dosing intervals and increasing the 
patient compliance. 
       The preparation of Esomeprazole tables is done by direct compression method. The 
evaluation of the formulated tablets was to be carried out on the parameters such as hardness, 
weight variation, drug content, friability and dissolution. 
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                                                   2.1 PLAN OF WORK 
The work was planned to carryout study in the sequences below:  
1. Formulation of Esomeprazole Sustain Release tablets using guar gum, xanthan gum and 
pectin. 
2. Evaluation of blend characteristics / Pre compression Characteristics of Esomeprazole 
Sustain Release tablet blends.  
 Angle of repose 
 Bulk density 
 Tapped density  
3.  Evaluation of Post compression Characteristics of Esomeprazole Sustain Release tablets.  
 Hardness 
 Friability 
 Uniformity 
 Weight variation 
3. Selection of best formulation on the basis of in-vitro drug release. 
4. Stability study on formulations as ICH guideline. 
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                                                    3. LITERATURE REVIEW 
 Uttam mandal et.al, (2008)8 design and studied an oral sustained release matrix tablet of 
metformin HCl and to optimize the drug release profile using response surface methodology. 
Tablets were prepared by non-aqueous wet granulation method using HPMC K15M as 
matrix forming polymer.  
 Syed Nisar Hussain Shah et.al, (2009)9  carried their research work on to design oral 
sustained release matrix tablets of water-insoluble drug, flurbifrofen, using natural gums as 
the matrixs polymers and to evaluate the drug release characteristics using response surface 
methodology. Matrix tablets were prepared by direct compression technique. Xanthan and 
acacia gums were taken as the independent variables. The formulated matrix tablets followed 
zero-order kinetics with negligible drug release. The objective of study to produce a 
formulation avoiding the gastric effects of flurbiprofen. 
 Vinayak Dhopeshwarkar et.al, (1994)10  prepared and evaluated sustained release 
cephalexin tablet formulation containing xanthan gum and sodium alginate in human 
volunteers. The formulation based on response surface analysis and computer simulation of 
cephalexin plasma levels Vs time curves. The SR matrix formulation is an alternative 
delivery method to produce prolonged concentration. 
 John W.Skoug et.al, (1993)11 developed a method to evaluate the drug release mechanism of 
matrix sustained release (SR) tablets by comparison of the drug and polymer release profiles. 
The method was applied to SR dosage forms of flurbiprofen, adinazolam mesylate and 
alprazolam, which encompass a wide range of drug solubility and formulation composition. 
The measurement of polymer release is a simple and rapid method of estimating the relative 
contributions of erosion and diffusion to the overall release mechanism. 
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 Ayhan Savaser et.al, (2004)12studied the effects of formulation variables on the release 
profile of diclofenac sodium (DS) from hydroxypropylmethyl cellulose (HPMC) and 
chitosan matrix tablets prepared by wet granulation and direct compression methods and 
different ratios of HPMC and chitosan were used. 
  P.G. Yeole et.al, (2006)13 developed sustained release matrix tablets of diclofenac sodium 
by using different drug: polymer ratios. Xanthan gum was used as matrix former, and 
microcrystalline cellulose as diluent. All the lubricated formulations were compressed using 
8 mm flat faced punches. Compressed tablets were evaluated for uniformity of weight, 
content of active ingredient, friability, hardness, thickness, in vitro dissolution using basket 
method, and swelling index. All the formulations showed compliance with pharmacopoeial 
standards. 
 D.M. Morkhade et.al, (2006)14 evaluated natural gum copal and gum damar as novel 
sustained release matrix forming materials in tablet formulation using Diclofenac sodium as a 
model drug and concluded that both gums possess substantial matrix forming property that 
could be used for sustained drug delivery 
 Umit Gonullu et al (2006)15 were developed 100 mg Opipramol 2-HCl (OP) matrix tablets 
by direct compression method in order to use once a day to provide patient compliance and 
constant blood level, consequently to decrease side effects. Two concentrations of polymers 
(10% and 20%): hydroxypropylcellulose (HPC) and hydroxypropyl methylcellulose 
(HPMC), sodium alginate (NaAlg), xanthan gum (XG) and Carbopol®941 (C941) were used 
in preparation of matrix tablets.is used for therapy of general somatoform and anxiety 
disorders. OP  
 A.K.Srivastava et.al, (2005)16 floating matrix tablets of atenolol were developed to prolong 
gastric residence time and increase drug bio availability. Atenolol was chosen as a model 
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drug because it is poorly absorbed from lower gastrointestinal tract. The tablets were 
prepared by direct compression technique. Tablets evaluated by hardness, swelling index, 
floating capacity, thickness and weight variation. The tablets exhibited controlled drug and 
prolong drug release profiles while floating over the dissolution meadium. 
 Phaechamud T et.al, (2005)17 designed and studied coated valproic acid and sodium 
valproate sustained-release matrix tablets by wet granulation technique. Colloidal silicon 
dioxide effectively adsorbed liquid valproic acid during wet granulation and granule 
preparation. The amounts of colloidal silicon dioxide and hydroxy propyl methyl cellulose 
employed in tablet formulations affected drug release from the tablets. The drug release was 
prominently sustained for over 12 h using hydroxy propyl methyl cellulose-based hydrophilic 
matrix system. Eudragit L 30 D-55 was used as effective subcoating material for core matrix 
tablets before over coating with hydroxy propyl methyl cellulose film with organic base 
solvent. 
 Singh Brahma N. et.al,(2000)18, Floating drug delivery system; an approach to oral 
controlled drug delivery via gastric retention have been made for rate- controlled drug 
delivery by overcoming physiological properties, such as gastric residence times (GRT) and 
unpredictable gastric emptying time (GET). 
 
 Xiao Qiang Xu et.al,(2006)19 floating matrix dosage form for phenoporlamine HCL based 
on gas forming agent; In this work the in-vitro an in-vivo evaluation of formulation was 
done. Formulation showed increased bioavailability with good floating properties. 
 
 Sunthongjeen Srisagul et.al,(2008)20 designed and evaluated of floating multi-layer tablets 
based on gas formation were developed. In this work gas generating agent (sodium 
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bicarbonate), protective layer (HPMC) and acrylic polymers (eudragit RL 30 D, NE 30 D) 
were used. Formulation showed good floating properties and sustained drug release was 
achieved. 
 
 Baumgartner Sasa et.al,(2000)21 Optimization of floating matrix tablets and evaluation of 
their gastric residence time. In this work tablet containing hydroxyl propyl methyl cellulose 
(HPMC), drug and different additives were compressed, and incorporation of gas generating 
agent together with microcrystalline cellulose. Formulated tablet didn‟t adhere tablet to the 
stomach mucus and that the mean gastric residence time was prolonged. 
 Streuble A. et.al,(2003)22 Floating matrix tablets based on low density foam powder; effects 
of formulation and processing parameters on drug release. In this work different types of 
matrix polymers were studied; hydroxypropyl methylcellulose, polycrylates, sodium alginate, 
corn starch, carrageenan, guar gum and gum Arabic. Formulation of floating behaviour of 
low density drug delivery showed accurate control of the drug release patterns. 
 
 Talwar Naresh et.al,(2009)23, Orally administered controlled drug delivery system 
providing temporal and spatial control. In this work various gas generating component, a 
swelling agent, viscolyzing agent, and optionally a gel forms polymer were used, causing the 
tablet or capsule to be retained in the stomach or upper part of the small intestine (spatial 
control). 
 
 Jaimini M. et.al,(2007)24Formulation and Evaluation of Famotidine floating tablets was 
reported. Different grades of Methocel K100 and Methocel K15M were used for gel forming 
properties, sodium bicarbonate was incorporated as gas generating agent. The drug release 
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from the tablet was sufficiently sustained and non-Fickian transport of drug from tablets was 
confirmed. 
 Khalil et.al, (2014)25 developed different formulas of 500 mg amoxicillin as sustained release 
layer by wet granulation method; similarly, different formulas of 20 mg esomeprazole in form 
of enteric coated pellets was prepared as extended release matrix layer by direct compression 
technique, using pH-independed hydrophilic Eudragit polymers (ERL100 and E-RSPM type) 
as matrix forming agent.The physical characteristics and release properties for compressed 
amoxicillin and esomeprazole matrix tablets were studied in addition the effect of polymer 
type, polymer concentration,polymer combination and ratio, effect of diluent type, binder type 
and method of preparation on the release of amoxicillin and esomeprazole from compressed 
matrix tablets. And results showed that amoxicillin can be prepared as a sustained release 
tablets using HPMC K100 and Xg. as matrix forming polymers in a polymer-polymer ratio of 
4:1, respectively. Also, esomeprazole can be prepared as extended release multi particulate 
tablets using pH-independed hydrophilic Eudragit polymers (E-RSPM type) as matrix forming 
agentwith EC. 
 A.K.L. Kabir et.al, (2009)26 were made attempt to develop esomeprazole sustained release 
matrix tablet using hydroxypropyl methylcellulose (HPMC) polymer such as Methocel K4M 
CR by direct compression method. Various amount of Methocel K4M CR was used to develop 
matrix builder in the seven proposed formulations (F1-F7) for the study of release rate 
retardant effect at 20%, 25%, 30%, 35%, 40%, 45% and 50% of total weight of tablet matrix 
respectively. From in vitro dissolution study, the formulation F-5 (40%) and F-6 (45%) met the 
official release pattern of esomeprazole for 10h period. The release mechanisms were explored 
and explained by Zero order, Higuchi, First order and Korsmeyer-Peppas equations. The 
release kinetics of formulation F-5 and F-6 very closely followed Higuchi kinetic order than 
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first order and zero order kinetics. From Korsmeyer- Peppas equation it was found that the 
drug release followed both diffusion and erosion mechanism in all cases. 
 Muthadi Radhika Reddy et.al, (2017)27 were prepared sustained release tablets by direct 
compression method usingcarbopol 934 and xanthan gums, hydroxylpropylmethylcellulose 
as polymers.The tablets were evaluated for their micromeritic properties and invitro release 
as well as by Fourier transform infrared (FTIR).The data showed FTIR and DSC results 
indicate that the drug was Compatible with the polymers used. Among all formulationsF2 
showed the most suitable sustained release properties with99.65% of drug 
releaseattheendof12h.Theresults indicated that a decrease In release kinetics of the drug was 
observed by increasing the polymer concentration.The release data was fitted to various 
mathematical models such as, Higuchi,Korsmeyer- Peppas, First-order,and Zeroorder toe 
valuate the kinetics and mechanism of the drug release. From this studies it s is concluded 
that the Tablets prepared with xanthan gum were revealed that increase in the concentration 
retards the drug release and can be used as a sustained release delivery system for 
Esmoprazole.                
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4.DRUGS AND EXCIPIENTS PROFILE 
4.1 ESOMEPRAZOLE28-29 
            Name 
                            Esomeprazole 
          Struture 
 
Fig 4.1 structure of esomeprazole 
 
              Categories                                         
 
 
 
 Anti-Ulcer Agents 
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Chemical   Formula 
 Enzyme Inhibitors 
 Proton-pump Inhibitors 
 Antihistamines 
 
   C17H19N3O3S 
5-methoxy-2-[(R)-[(4-methoxy-3,5-dimethylpyridin-2-
yl)methane]sulfinyl]-1H-1,3-benzodiazole 
                              
IUPAC Name 
PharmacologyIndication 
         For the treatment of acid-reflux disorders (GERD), peptic ulcer disease, H. pylori 
eradication, and prevention of gastroinetestinal bleeds with NSAID use. 
Pharmacodynamic 
        Esomeprazole is a compound that inhibits gastric acid secretion and is indicated in the 
treatment of gastroesophageal reflux disease (GERD), the healing of erosive esophagitis, and 
H. pylori eradication to reduce the risk of duodenal ulcer recurrence. Esomeprazole belongs to 
a new class of antisecretory compounds, 
The substituted benzimidazoles, that do not exhibit anticholinergic or H2 histamine 
antagonistic properties, but that suppress gastric acid secretion by specific inhibition of the 
H+/K+ ATPase at the secretory surface of the gastric parietal cell. By doing so, it inhibits acid 
secretion into the gsatric lumen. This effect is dose-related and leads to inhibition of both 
basal and stimulated acid secretion irrespective of the stimulus. 
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Mechanism of Action 
   
              Esomeprazole is a proton pump inhibitor that suppresses gastric acid secretion by 
specific inhibition of the H+/K+-ATPase in the gastric parietal cell. By acting specifically on 
the proton pump, Esomeprazole blocks the final step in acid production, thus reducing 
gastric acidity. 
 
Absorption        
  90%  
Volume of distribution 
16 L [healthy volunteers] 
Protein binding 
97% 
Metabolism 
                                
        Mainly hepatic. Esomeprazole is completely metabolized by the cytochrome P450 
system via CYP2C19 and CYP3A4. Metabolism produces inactive hydroxy and desmethyl 
metabolites, which have no effect on gastric. Less than 1% of the parent drug is excreted in 
urine. 
 
Route of elimination: 
        Approximately 80% of the administered dose of esomeprazole is excreted as 
metabolites in urine and the remaining 20% is excreted in feces. 
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Half life 
                               
       1-1.5 hours 
Toxicity 
       Blurred vision, confusion, drowsiness, dry mouth, flushing headache, nausea, rapid 
heartbeat, sweating 
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4.2 XANTHAN GUM30 
Synonym: 
         Corn sugar gum; polysaccharide B-1459; Rhodigel;Vanzan NF; Xantural. 
Description: 
      Xanthan gum occurs as a cream- or white-colored, odorless, free-flowing, fine 
powder. 
 
Molecular Formula: 
      (C35H49O29)n 
 
Solubility: 
     Practically insoluble in ethanol and ether; soluble incold or warm water 
 
Viscosity: 
      1200–1600 mPa s (1200–1600 cP) for a 1% w/vaqueous solution at 258°C 
Functional category: 
      Gelling agent; stabilizing agent; suspending agent; sustained-release agent; 
viscosity-increasing agent 
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Grade: 
        Keltrol CG, Grindsted Xanthan 80, Vanzan NF 
Stability and storage condition: 
        Aqueous solutions are stable over a wide pH range (pH 3 –12), although they 
demonstrate maximum stability at pH 4–10 and temperatures of 10–608°C 
 
Incompatibilities:  
         Xanthan gum is an ionic material and is not usually compactable with cationic surfactance 
polymers or preservatives as precipitation occurs 
Application: 
        Xanthan gum is used to prepare sustained -release matrix. Xanthan gum has also  
been used to produce d i r e c t l y  c o m p r e s s e d  m a t r i c e s  t h a t  d i s p l a y  a  h i g h  degree of 
swelling due to water uptake, and a small amount of erosion due to polymer relaxation. 
 
Safety: 
         The estimated acceptable daily intake for xanthan gum has been set by WHO at upto 
10mg/kg body weight 
 
 
  
                                    33 
4.3 GUAR GUM30 
                  Guar gum is a naturally occurring galactomannan polysaccharide; consists of chiefly 
high molecular weight hydro colloidal polysaccharide, composed of galactan and mannan units 
combined through glycoside linkages and shows degradation in the large intestine due to the 
presence of microbial enzymes. It contains about 80% galactomannan, 12% water, 5% protein, 
2% acid soluble ash, and 0.7% fat. Guar gum has a molecular weight of approximately 1 million, 
giving it a high viscosity in solution. The high viscosity of guar gum results from its high 
molecular weight and long chain. 
 
Chemistry of Guar Gum: 
                  A guar gum molecule is made up of about 10,000 residues, which are non-ionic 
polydisperse rod-shaped polymers. The structure of guar gum is a linear chain of β-
Dmannopyranosyl 
 
 
Fig.no:4.2: Structure of guar gum 
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Properties of Guar Gum 
                  The most important property of guar gum is its ability to hydrate rapidly in cold water 
to attain uniform and very high viscosity at relatively low concentrations. Apart from being the 
most cost-effective stabilizer and emulsifier it provides texture improvement and water binding, 
enhances mouth feel and controls crystal formation. 
The main properties of guar gum are: 
 It is soluble in hot & cold water but insoluble in most organic solvents and has strong 
hydrogen bonding properties. 
 It has excellent thickening, emulsion, stabilizing and film forming properties, excellent 
ability to control rheology by water phase management. 
 The viscosity of guar gum is influenced by temperature, pH, presence of salts and other 
solids. 
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4.4 PECTIN30 
                Pectin is a naturally occurring biopolymer that is finding increasing applications in the 
pharmaceutical and biotechnology industry. It has been used successfully for many years in the 
food and beverage industry as a thickening agent, a gelling agent and a colloidal stabilizer. 
Pectin also has several unique properties that have enabled it to be used as a matrix for the 
entrapment and/or delivery of a variety of drugs, proteins and cells. This review will first 
describe the source and production, chemical structure and general properties of pectin. The 
methods of gel formation and properties of the gels will then be discussed. Finally, some 
examples of the pharmaceutical uses of pectin will be given. 
Chemistry of pectin 
                  Pectin is an essentially linear polysaccharide. Like most other plant polysaccharides, 
it is both polydisperse and polymolecular and its composition varies with the source and the 
conditions applied during isolation. In any sample of pectin, parameters such as the molecular 
weight or the content of particular subunits will differ from molecule to molecule. The 
composition and structure of pectin are still not completely understood although pectin was 
discovered over 200 years ago. 
 
Fig.no: 4.3: Structure of Pectin 
  
                                    36 
Pharmaceutical uses of pectin: 
 Pectin has applications in the pharmaceutical industry. Pectin favorably influences 
cholesterol levels in blood. It has been reported to help reduce blood cholesterol in a wide 
variety of subjects and experimental conditions. 
 Pectin acts as a natural prophylactic substance against poisoning with toxic cations. It has 
been shown to be effective in removing lead and mercury from the gastrointestinal tract 
and respiratory organs. 
 Pectin reduces rate of digestion by immobilizing food components in the intestine. This 
results in less absorption of food. 
 The thickness of the pectin layer influences the absorption by prohibiting contact between 
the intestinal enzyme and the food, thus reducing the latter‟s availability. 
 Pectin hydro gels have been used in tablet formulations as a binding agent (Slaney et al., 
1981a,b) and have been used in controlled-release matrix tablet formulations. 
 Pectin has a promising pharmaceutical uses and is presently considered as a carrier 
material in colon-specific drug delivery systems. 
 Pectin is an interesting candidate for pharmaceutical use, e.g. as a carrier of a variety of 
drugs for controlled release applications. Many techniques have been used to 
manufacture the pectin-based 
 delivery systems, especially ionotropic gelation and gel coating. These simple techniques, 
together with the very safe toxicity profile, make pectin an exciting and promising 
excipient for the pharmaceutical industry for present and future applications. 
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4.5 POVIDONE30 
Chemical name:  
                 1-Ethenyl-2-pyrrolidinone homopolymer 
Synonym:  
               E1201, Kollidon, Plasdone, poly [1-(2-oxo-1-pyrrolidinyl)ethylene], polyvidone, 
Polyvinylpyrrolidone, PVP, 1-vinyl-2-pyrrolidinone polymer. 
Description:  
                Povidone occurs as a fine, white to creamy-white colored, odorless or almost odorless, 
hygroscopic powder. Povidones with K-values equal to or lower than 30 are manufactured by 
spray-drying and occur as spheres. Povidone K-90 and higher K-value povidones are 
manufactured by drum drying and occur as plates. 
               The USP 28 describes povidone as a synthetic polymer consisting essentially of linear 
1-vinyl-2-pyrrolidinone groups, the differing degree of polymerization of which results in 
polymers of various molecular weights. It is characterized by its viscosity in aqueous solution, 
relative to that of water, expressed as a K-value, in the range 10–120. The K-value is calculated 
using fikentscher‟s equation 
 
Where z is the relative viscosity of the solution of concentration c (in % w/v), and k is the K 
value× 10–3. 
Alternatively, the K-value may be determined from the following equation, 
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Where z is the relative viscosity of the solution of concentration c (in % w/v). 
 
Solubility:  
               Freely soluble in acids, chloroform, ethanol (95%), ketones, methanol, and water; 
practically insoluble in ether, hydrocarbons, and mineral oil. In water, the concentration of a 
solution is limited only by the viscosity of the resulting solution, which is a function of the K-
value 
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Table.no:4.1. Approximate molecular weights for different grades of povidone 
K-value Approximate molecular weight 
12 2,500 
15 8,000 
17 10,000 
25 30,000 
30 50,000 
60 400,000 
90 1 000,000 
120 3 000,000 
                           pH: 3.0–7.0 
                          Bulk density: 0.29–0.39 g/cm3 
                          Tapped density: 0.39–0.54 g/cm3 
                          Specific surface area: 0.24 m2/g 
                          Melting point: Softens at 150°C 
                         Incompatibilities; Sodium starch glycolate is incompatible with ascorbic acid. 
                        Pharmaceutical uses: Disintegrant, dissolution aid, suspending agent, tablet 
binder. 
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4.6 MICRO CRYSTALLINE CELLULOSE30: 
Synonyms:  
          Avicel PH, Celex, cellulose gel, celphere. 
Empirical formula and molecular weight: 
         (C6H10O5)n    =  36000W ,Where, n = 220. 
Structure: 
 
Fig.no:4.4: Structure of Micro crystalline cellulose 
 
Functional category:  
                  Adsorbent, suspending agent, tablet and capsule diluent, tablet disintegrant. 
Description:  
                  Microcrystalline cellulose is purified, partially depolymerized cellulose that occurs as 
a white, odorless, tasteless, crystalline powder composed of porous particles. 
pH: 5.0 -7.5 
Melting point: 260 - 2700C 
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Stability: It is stable though hygroscopic material. 
Storage: Should be stored in well closed container in a cool, dry place. 
Safety : Non- toxic and non-irritant material. Consumption of large quantities of cellulose may         
have a laxative effect 
Handling precautions: It may be irritant to eyes Gloves, eye protection and a dust mask is 
recommended 
Applications in pharmaceutical formulation or technology: 
 Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both wet-
granulation and direct-compression processes. 
 In addition to its use as binder/diluents, microcrystalline cellulose also has some lubricant 
and disintegrant properties that make it useful in tableting. Microcrystalline cellulose is 
also used in cosmetics and food products. 
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4.7 MAGNESIUM STEARATE30: 
Synonyms:  Magnesium octadecanoate; octadecanoic acid, magnesium salt; stearic acid. 
Chemical Name: Octadecanoic acid magnesium salt. 
Empirical Formula: C36H70MgO4 
Description: Magnesium stearate is a very fine, light white, precipitated or milled, impalpable 
powder of low bulk density, having a faint odor of stearic acid and a characteristic taste. The 
powder is greasy to touch and readily adheres to the skin. 
Molecular Weight: 591.34 
Functional category: Tablet and capsule lubricant. 
Stability and Storage Conditions: It is stable and should be stored in a well closed container in 
a cool, dry place. 
Safety : Magnesium stearate is widely used as a pharmaceutical excipient and is generally 
regarded as being nontoxic following oral administration. However, oral consumption of large 
quantities may produce a laxative effect or mucosal irritation. 
Applications in Pharmaceutical Formulation or Technology: 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical formulations. 
It is primarily used as an lubricant in capsule and tablet manufacture at concentrations between 
0.25% and 5.0% w/w. It is also used in barrier creams. 
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4.8 PURIFIED TALC30 
Synonyms: Hydrous magnesium calcium silicate; hydrous magnesium silicate; powdered talc; 
purified French chalk; Pure talc; soapstone; steatite; Superiore. 
Empirical formula and molecular weight: Talc is a purified, hydrated, magnesium silicate, 
approximating to the formula Mg6 (Si2O5)4(OH)4. It may contain small, variable amounts of 
aluminum silicate and iron. 
Functional category: Anticaking agent; glidant; tablet and capsule diluent; tablet and capsule 
lubricant. 
Applications: Talc is also used as a lubricant in tablet formulations; in a novel powder coating 
for extended-release pellets; and as an adsorbant. In topical preparations, talc is used as a dusting 
powder, although it should not be used to dust surgical gloves. Talc is additionally used to clarify 
liquids and is also used in cosmetics and food products, mainly for its lubricant properties. Talc 
was once widely used in oral solid dosage formulations as a lubricant and diluent. 
Stability and storage conditions: Talc is a stable material and may be sterilized by heating at 
160o C for not less than 1 hour. It may also be sterilized by exposure to ethylene oxide or gamma 
irradiation. Talc should be stored in a well-closed container in a cool, dry place. 
Incompatibilities: Incompatible with quaternary ammonium compounds. 
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5. MATERIALS AND METHODS 
5.1 MATERIALS USED 
Tab 5.1 shows list of material used for this proposed work 
Sno Name of the 
material 
Source from 
1 Esomeprazole Mylan, Hyderabad. 
2 Xanthum gum Serin Formulations 
pvt.ltd 
3 Guar gum Mylan, Hyderabad. 
4 Pectin (Standard chemicals 
5 Microcrystalline 
cellulose 
Standard chemicals 
6 PVP K30 Standard chemicals 
7 Talc  Standard chemicals 
8 Magnesium stearate 
– Lubricant 
Standard chemicals 
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Table 5.2 List of Instruments/equipments used. 
Equipments Modified/Manufacturer 
Double rotary tablet compression 
machine 
Hardness tester, Pfizer 
Friabilator 
pH meter 
Dissolution Apparatus 
Double beam spectrophotometer 
FT-IR Spectrophotometer 
 
Karunavati Pvt Ltd., Rajasthan (RIMEK 
minipress) 
Mitutoyo South Asia Pvt Ltd., New 
Delhi 
Roche Friabilator 
Shankar Scientific, Chennai 
Lab india disso-2000 
Shimadzu Scientific Instruments, Japan 
Shimadzu Scientific Instruments, Japan 
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  5.2 Formulation table for design of Sustained release tablets of Esomeprazole: 
Table no: 5.3 :  Design of Sustained release tablets of Esomeprazole 
Formulation 
code 
/ compositions 
F1 
(mg) 
F2 
(mg) 
F3 
(mg) 
F4 
(mg) 
F5 
(mg) 
F6 
(mg) 
F7 
(mg) 
F8 
(mg) 
F9 
(mg) 
F10 
(mg) 
F11 
(mg) 
F12 
(mg) 
Esomeprazole 20 20 20 20 20 20 20 20 20 20 20 20 
Xanthum gum 10 20 40 60 - - - - - - - - 
Guargum - - - - 10 20 40 60 - - - - 
Pectin - - - - - - - - 10 20 40 60 
Microcrystalline 
cellulose 
63.8 53.8 33.8 13.8 63.8 53.8 33.8 13.8 63.8 53.8 33.8 13.8 
PVP K30 5 5 5 5 5 5 5 5 5 5 5 5 
Talc 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 
Magnesium 
stearate 
0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 0.6 
Total 100 100 100 100 100 100 100 100 100 100 100 100 
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5.2.1 Formulation of Esomeprazole matrix tablets: 
The matrix tablets were prepared by following the General Methodology as given below: 
 The procedure followed was direct compression. 
 The drug and all the excipients except magnesium stearate and talc were weighed 
appropriately and were passed through sieve no.30. 
 Magnesium stearate and talc were passed through mesh no.60. 
 All the ingredients were mixed thoroughly in a polythene bag and compressed to a tablet. 
 
5.3 EVALUATION OF BLEND CHARECTERISTICS 
5.3.1 Pre compression characteristics of Esomeprazole matrix tablets 
5.3.1.1 Drug and excipients compatibility studies  
 
              FTIR spectroscopy was carried for pure drug and polymers to know any chemical 
interactions between polymers and drug. The samples of pure drug, polymers and physical 
mixture of drug and polymers were dispersed in 200 mg of KBr powder and compressed into 
pellets at a pressure of 6000 kg/cm2 and analyzed. Spectral measurements were obtained by 
powder diffuse reflectance on a FT-infrared spectrophotometer (Shimadzu, FT-IR, Japan) in 
the range 4000 – 400 cm-1. 
 
5.3.1.2 ANGLE OF REPOSE:  
                 The flow property was determined by measuring the Angle of Repose. In order to 
determine the flow property, the Angle of Repose was determined. It is the maximum angle that 
can be obtained between the free standing surface of a powder heap and the horizontal plane. 
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   θ = tan-1 (h/r) 
Where,  h = height 
   r = radius 
   θ = angle of repose 
Procedure: 
 20gms of the sample was taken 
 The sample was passed through the funnel slowly to form a heap. 
 The height of the power heap formed was measured 
 The circumference formed was drawn with a pencil on the graph paper. 
 The radius was measured and the angle of repose was determined.  This was repeated 
three times for a sample. 
  
 
5.3.1.3. COMPRESSIBILITY INDEX: 
                   The flow property was also determined by measuring the compressibility index (I) 
(flowability).  A simple indication of the case with which a material can be induced to flow is 
given by application of a compressibility index (I) given by equation. 
                       I = [1 – (V/V0)] x 100 
   Where „V‟ the volume occupied by a sample of the power after being subjected to a 
standardized tapping procedure (after 500 vibrations) and „V0‟ in the volume before tapping. 
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Procedure: 
1.  10gms of the final blend was taken in a 50 ml – measuring cylinder. 
2. Measured the initial volume before tapping of the three measuring cylinder. 
3. After 500 tapings, occupied volume was determined for the measuring cylinder. 
4. The compressibility index (I) was determined by using above equation. 
5.3.2 Evaluation of post compression characteristics:  
The following evaluation of tablets was performed. 
 Weight variation 
  Hardness 
 Friability 
 Content uniformity 
 
5.3.2.1 WEIGHT VARIATION 
                  The USP weight variation test was run by weighing 20 tablets individually, 
calculating the average weight, and comparing the individual tablet weights to the average. The 
tablets met the USP test that was no more than 2 tablets were outside the percentage limit and no 
tablets differed by more than 2 times the percentage limit. 
       
5.3.2.2 HARDNESS  
                 Hardness of the tablets was determined by breaking it between the second and third 
fingers with thumb being as a fulcrum. There was a sharp snap the tablet was deemedto have 
acceptable strength. 
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               Hardness of the tablets are also determined by Stokes Monsanto Hardness Tester and 
the hardness should be found within the range of 3.5-5.5 kg/cm². 
5.3.2.3 FRIABILITY 
              The friability of tablets was determined by Roche friabilator. 20 tablets were taken and 
weighed. After weighing the tablets were placed in the Roche friabilator and subjected to the 
combined effects of abrasion and shock by utilizing a plastic chamber that revolves at 25RPM 
/100 revolutions by dropping the from a distance of six inches with each revolution .after 
operation the tablets were deducted and reweighed . 
Friability is determined by 
                      F=100(1-Wo/Wt) 
Where, 
Wo= wt. of tablets before friability test. 
 Wt= wt. of tablets after friability test.  
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5.3.2.4 CONTENT UNIFORMITY 
                 Five tablets were weighed and powdered, 10 mg of equivalent of Esomeprazole was 
weighed and dissolved in suitable quantity of methanol, the solution was filtered suitably diluted 
and the drug content was analyzed using UV spectrometer at 300nm.  
Table no 5.4: WEIGHT VARIATION TOLERANCE FOR UNCOATED TABLETS 
S.No. Average  weight  of  tablets (mg) Maximum  percentage difference 
allowed 
1 130 or less 10 
2 130 to 324 7.5 
3 More than 324 5 
 
5.4.1 IN -VITRO DISSOLUTION STUDIES OF ESOMEPRAZOLE SUSTAINED 
RELEASED TABLETS: 
 Apparatus II (Paddle Method) 
                The same equipment as in apparatus I was used, expected that a paddle replaced the 
basket, formed from a blade and a shaft as a stirring element. The dosage form was allowed to 
sink to the bottom of the flask before stirring. A constant temperature of 37±0.5 ºC was 
maintained. The motor was adjusted to turn at the specified speed of 50rpm, and the samples of 
the fluid were withdrawn at intervals to determine the amount of drug in solution. 
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 DISSOLUTION OF ESOMEPRAZOLE SUSTAINED RELEASE TABLETS. 
               The dissolution test was carried out using USP apparatus II (Lab india disso-
2000).Stirring speed was maintained at 50rpm. 6.8 pH phosphate buffers were used as 
dissolution medium (900ml) and were maintained at 37±0.5c. Samples of specified volume were 
withdrawn at predetermined time intervals, filtered, dilute suitably and assayed 
spectrophotometrically. An equal volume of fresh medium was immediately replaced to maintain 
the dissolution volume. The sample was analyzed spectrophotometrically at 300 nm. Using 
spectrophotometer to assay the amount of Esomeprazole released at each time interval. 
5.5 KINETIC MODELS 
Release Kinetics   
          To analyses the mechanism for the drug release and drug release rate kinetics of the 
dosage form, the data obtained was fitted in to Zero order and First order model. In this by 
comparing the R-values obtained, the best-fit model was selected. 
Zero Order Kinetics 
               This model describes the system where the release rate is independent of the 
concentration of the dissolved species. 
This following relation can in a simply express this model. 
                                          
Where, Qt= Amount of drug dissolved in time t,  
Qo = Initial amount of drug in the solution and 
Ko = Zero order release constant. 
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First Order Kinetics 
                     The first order equation describes the release from systems where the dissolution 
rate is dependent upon the concentration of the dissolving species. 
         To study the first order release rate kinetics, the release rate data were fitted to the 
following equation. 
                               log Qt = log Qo + K1t / 2.303 
Where,  
           Qt = Amount of drug released in time t, 
Qo = Initial amount of drug in the solution and 
K1 = First order release constant. 
 
Higuchi Model 
                     A large number of modified release dosage form contain some sort of matrix 
system. In such instances, the drug dissolves from the matrix. The dissolution pattern of the 
drug is dictated by  water penetration rate (diffusion controlled) and thus the following 
relationship applies as formula: 
                                                 Q = k 2 t
1/2    
 
    Where Q is the percent of drug release at time t, and k2  is the diffusion rate constant 
In higuchi model, a plot of % drug released versus square root of time is linear.        
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      5.6 STABILITY STUDIES 
                       Short term stability studies were carried out the optimized (F8) formulation 
Adequate number of tablets were filled in amber colored rubber Stoppard bottles and reserve in 
stability compartment maintained at temperature at 40 ± 2ºC / 75 ± 5% RH for three months 
were analyzed regularly, for their physical appearance, friability, drug content, and in-vitro drug 
release. 
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                                                 6. RESULTS AND DISCUSSION 
PREFORMULATION STUDIES 
Table no: 6.1 pre-formulation study results of Esomeprazole  
 
 
 
 
  
S.No. Test Specification Results 
1. 
Organoleptic properties   
Color White to off-white White to off-white 
Odor Odorless Odorless 
Nature Amorphous Amorphous 
2. Solubility slightly soluble in water 
Slightly soluble in 
water 
3. LOD 
NMT 0.5% of its 
weight 
0.25% 
4. Melting Point 155º C 155 º C 
5. Assay 
NLT 98.0% and NMT 
102.0% 
99.86% 
6. Particle size analysis 3-5mm 4mm 
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DISCUSSION:  
                      The description of the drug was observed visually. The solubility data reveals that 
the drug is freely soluble and is a member of class III drugs according to the BCS classification.  
                     The LOD data was observed indicating that the API is non-hygroscopic. The 
melting point of the Esomeprazole was performed using melting point apparatus. The particle 
size analysis was performed by microscopic method. 
 
Flow properties of Esomeprazole: 
Table no: 6.2 Flow properties of Esomeprazole 
S.No. Parameter Results 
1. Bulk density (gm/cc) 0.55 gm/cc 
2. Tapped Density (gm/cc) 0.64 gm/cc 
3. Compressibility Index(%) 16.36% 
4. Hausner‟s Ratio 1.16 
 
DISCUSSION:  
                  The Flow indices Hausners ratio and Compressibility index shows that API has good 
flow. Consequently direct compression was followed for the manufacture of Matrix release 
tablets. 
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Drug and excipients compatibility studies  
 
 
Figure 6.1 FTIR spectra of pure Esomeprazole 
 
 
Figure 6.2  FTIR spectra of pectin 
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Figure: 6.3 FTIR spectra of guar gum  
 
Figure:6.4  FTIR spectra of xanthan gum 
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Figure:6.5  FTIR spectra of physical mixture of Esomeprazole and polymers 
 
 
 
DISCUSSION 
 
                   FT-IR spectra of the pure drug shown in figure 6.1. The broad peak at 3897.44cm-1in 
the spectra of the pure drug corresponds to N-H (stretching). The peak at 1002.05 cm-
1corresponds to S=0 (stretching), the peak at 1155.47cm-1 for C-O-C (stretching). The drug and 
polymers employed were found to be compatible as similar peaks were observed with minor 
differences shown in figure 6.5 
Preparation of calibration curve for Esomeprazole: 
      1 gm of Esomeprazole was dissolved in 100 ml of pH 6.8 buffer by slight shaking 
(1000 mcg/ml). From the stock solution, suitable serial dilutions were made to get the 
concentrations of 1, 3, 5, 7 and 9 g/ml in pH 6.8 phosphate buffer solutions.   
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               The absorbance of these solutions were measured at 300 nm and standard plot was 
drawn using the data obtained. 
Table no 6.3: Calibration curve of Esomeprazole 
Sl.No. 
Concentration 
 (µg/ml) 
Absorbance  
(ƛ max =300nm) 
1. 1 0.035 
2. 3 0.110 
3. 5 0.191 
4. 7 0.280 
5. 9 0.367 
 
Fig.no:6. 6 : Calibration curve of Esomeprazole 
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Tab 6.4: Results of pre formulation evaluation  
Formulation 
code/Parameter 
Bulk density Tapped 
density 
Angle of 
repose 
Compressibility 
index 
Hausners 
ratio 
F1 0.462 ±0.01 0.591±0.06 26.06±0.12 21.8 1.25 
F2 0.469±0.01 0.561±0.02 25.42±0.98 21.39 1.19 
F3 0.46±0.02 0.55±0.01 22.62±0.28 16.36 1.19 
F4 0.59±0.05 0.68±0.04 29.19±1.20 13.04 1.15 
F5 0.49±0.06 0.57±0.07 27.40±1.21 14.04 1.16 
F6 0.48±0.02 0.55±0.06 26.06±0.90 12.72 1.14 
F7 0.46±0.02 0.53±0.06 24.38±1.21 13.20 1.15 
F8 0.43±0.04 0.49±0.04 23.72±1.23 12.24 1.14 
F9 0.41±0.03 0.47±0.01 21.94±2.12 12.76 1.14 
F10 0.39±0.02 0.44±0.02 20.48±1.33 11.36 1.12 
F11 0.55±0.21 0.64±0,02 26.21±1.78 14.06 1.16 
F12 0.53±0.02 0.61±0.02 25.74±1.23 13.11 1.15 
All values are expressed as Mean±SD 
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DISCUSSION  
     The λ max of Esomeprazole in 6.8 pH phosphate buffer was scanned and found to 
have the maximum absorbance at 300 nm. Standard graph of Esomeprazole in 6.8pH phosphate 
buffer was plotted and regression was 0.997. 
    The formulations were prepared with natural polymers like xanthum gum, guar gum 
and pectin and then evaluated. 
    The angle of repose values obtained for the formulations ranged from 20.48 to 27.40 
this indicates good flow property of the powder blends. 
    The compressibility index values for the formulations ranged from 11.36 to 21.8. This 
also indicates the powder blend have good flow property. 
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Tab 6.5: Results of post compression evolution   
Formulation 
code/Parameter 
Hardness(units) Weight 
variation 
Friability (%) Content 
uniformity 
F1 3.0±0.02 Pass 0.18±0.02 99.17±1.5 
F2 3.1±0.03 Pass 0.22±0.02 99.44±1.2 
F3 3.0±0.71 Pass 0.43±0.04 98.64±2.8 
F4 3.2±0.03 Pass 0.20±0.02 99.42±3.1 
F5 3.0±0.06 Pass 0.19±0.08 99.17±2.8 
F6 3.0±0.04 Pass 0.22±0.06 99.44±2.0 
F7 3.0±0.03 Pass 0.45±0.04 99.64±2.6 
F8 3.1±0.02 Pass 0.24±0.02 100.2±3.2 
F9 3.2±0.01 Pass 0.38±0.04 99.89±4.2 
F10 3.2±0.03 Pass 0.12±0.04 99.97±3.2 
F11 3.1±0.04 Pass 0.24±0.02 99.24±2.1 
F12 3.0±0.04 Pass 0.16±0.03 99.62±1.2 
All values are expressed as Mean±SD 
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DISCUSSION 
     The total weight of each formulation was not maintained uniformly however the 
weight variation of the tablets within the limits of 5%. 
The measured hardness of tablets in all batches was ranged from 3.0 – 3.2 kg/cm2. 
Friability values were found to be less than1% in all prepared formulations and 
considered to be satisfactory. 
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Tab 6.6: in vitro evaluation percentage of drug results  
Time 
(hr) 
F1(%) F2(%) F3(%) F4(%) F5(%) F6(%) F7(%) F8(%) F9(%) F10(%) F11(%) F12(%) 
1 42±1.2 43±2.2 31±1.1 32±1.8 42±2.4 33±2.1 26±1.5 22±1.8 46±1.9 44±1.0 36±2.4 32±2.6 
2  54±1.0 54±2.8 43±1.2 38±1.4 56±3.3 43±2.0 38±1.7 32±4.3 57±2.2 58±1.1 43±1.7 41±2.2 
4  65±3.1 61±2.2 52±1.4 46±1.7 61±3.4 57±4.8 46±1.1 41±2.2 67±3.3 66±1.3 55±1.3 51±2.0 
6 72±2.9 69±2.6 64±1.0 58±2.1 68±3.3 65±3.2 52±1.2 48±1.2 76±2.1 72±2.2 67±2.4 63±2.8 
8  86±2.2 76±2.4 67±1.9 66±2.2 75±3.9 72±2.1 64±2.1 56±3.1 93±1.8 86±2.8 74±3.2 69±1.8 
10 92±1.1 84±2.9 82±1.1 72±2.8 86±3.5 83±2.2 76±2.9 62±3.4 98±1.2 95±3.1 85±3.8 82±1.4 
12 97±3.2 93±3.0 89±1.3 85±2.2 93±2.2 89±3.5 83±2.7 69±2.8  98±2.1 92±2.1 89±3.1 
14   98±3.8 93±1.8 92±2.3 98±0.1 94±3.3 88±2.2 74±1.2   94±0.8 93±3.3 
16    98±1.8 94±2.9  98±3.2 92±2.1 82±1.1   98±1.8 95±2.3 
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18    97±1.1   95±0.2 90±0.4    97±2.1 
20       98±1.1 93±1.9     
22        97±0.9     
24        99±1.0     
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Fig.no:6. 7 : invitro cumulative percentage of drug release  
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Tab 6.7 shows release kinetic pattern of formulations 
Formulation F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Zero-order  
(R2) 0.496 0.417 0.667 0.698 0.417 0.609 0.705 0.775 0.529 0.449 0.589 0.612 
First order  
(R2) 0.959 0.9 0.966 0.939 0.905 0.973 0.975 0.981 0.925 0.94 0.977 0.983 
Higuchi 
order 
(R2) 0.949 0.924 0.984 0.983 0.921 0.982 0.989 0.995 0.948 0.931 0.979 0.988 
 
DISCUSSION 
    In vitro drug release profiles for all formulations were carried out by using 6.8pH 
phosphate buffer as dissolution medium for about 24 hrs. 
              From the above results it was found that the release of drug from formulation F8 which 
was composed of Guargum at 60 mg gave the better release, drug content, friability, hardness 
than other formulations. 
             The drug release from all the formulations were followed Higuchi model (Table 6.7). 
The Correlation Coefficients (r2) for the Higuchi model of drug release for the formulations are 
in the range of 0.921 to 0.995. The Higuchi plot between amounts of drug released as a function 
of the square root of time. The amount of drug released from the formulation F6, F7 and F8 
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increased linearly with the square root of time indicating that the diffusion of drug from the 
tablets, which is affected by the porosity and tortuosity of the matrix may be the rate-limiting 
step in the release of Esomeprazole from SR tablets. 
               Tab 6.8 Stability studies of optimized formulation(F8) 
Parameters 1st month 2nd month 3rd month 
Physical appearance No Change No Change No Change 
Friability  0.25±0.04 0.33±0.09 0.34±0.07 
Drug content 101.70±0.47 99.63±0.116 99.13±0.101 
In-vitro drug  release 99.57±0.53 100.49±0.55 99.43±0.79 
All values are expressed as Mean±SD 
 
DISCUSSION 
                 The stability study results of optimized formulation F8 reflect that there is no 
significant change in physical appearance, friability, drug content and dissolution profile of the 
formulation. Hence, it concludes that the tablets from this formulation are stable for the period 3 
months at 40 ±2°C.  
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7. SUMMARY AND CONCLUSION 
 
Esomeprazole is a proton pump inhibitor used in dyspepsia. The approach of the present 
study was to make a comparative evaluation among concentration of Natural polymers like 
xanthum gum, guar-gum and pectin and to assess the effect of physico-chemical nature of the 
active ingredients on the drug release profile.  
 The angle of repose, compressibility index and sieve analysis results shown that the 
formulation is suitable for direct compression. 
 This study have been showed that Esomeprazole could be used in sustained release drug 
delivery system by formulating it has sustained drug delivery system, provides extended duration 
of action in therapeutic range without reaching toxic levels as in the case of conventional dosage 
forms. These dosage forms have the ability to reduce the dosing frequency and increasing. 
 The technique employed in the preparation of matrix system i.e. direct compression, is 
highly practical and economical from the industry point of view.   
 The sustainability of the drug with Guar gum as a sustaining polymer at a concentration 
of 60 mg was found to show good sustainability when compared to the all other formulation, as it 
showed 99% drug release for 24 hrs.  
The optimized formulation dissolution data was subjected to release kinetics; from the 
release kinetics data it was evident that the formulation followed Higuchi mechanism of drug 
release 
 Success of the In vitro drug release studies recommends the product for further In vivo 
studies, it may improve patient compliance. 
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